Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
Abstract Background Atezolizumab plus bevacizumab has shown promising efficacy in advanced mucosal melanoma in the multi‐centre phase II study. This report updates 3‐year survival outcomes and multi‐omics analysis to identify potential response biomarkers. Methods Forty‐three intention‐to‐treat (ITT...
Saved in:
Main Authors: | Jie Dai, Tianxiao Xu, Lifeng Li, Meiyu Fang, Jing Lin, Jun Cao, Xue Bai, Caili Li, Xiaoting Wei, Junjie Gu, Yaoyao Liu, Xuan Gao, Xuefeng Xia, Jun Guo, Yu Chen, Lili Mao, Lu Si |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Clinical and Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/ctm2.70169 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
by: Ryosuke Tsunemitsu, et al.
Published: (2023-06-01) -
Brain hemorrhage in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
by: Bangju Kim, et al.
Published: (2025-06-01) -
Retrospective Multicentre Real-Life Study Evaluating the Efficacy of Atezolizumab Combined with Bevacizumab for the Treatment of Metastatic Hepatocellular Carcinoma: HIREAL Study
by: Barbe-Richaud JB, et al.
Published: (2025-07-01) -
Atezolizumab and Bevacizumab in Therapy for Patients with Hepatocellular Carcinoma in Real Clinical Practice
by: G. A. Serebrennikov, et al.
Published: (2023-07-01) -
Retinal Blood Flow Decreases after Treatment with Bevacizumab for Retinopathy of Prematurity
by: Joyce Wang, BS, et al.
Published: (2025-11-01)